Join
Live feed
·
PRReleasevia Quantisnow
Syndax Pharmaceuticals Inc. logo

Syndax Announces Positive Data for Revumenib in Patients with Acute Leukemias from the BEAT AML, SAVE AML and AUGMENT-102 Phase 1 Combination Trials

ByQuantisnow·Wall Street's wire, on your screen.
SNDX· Syndax Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SNDX (Syndax Pharmaceuticals Inc.) and more on Quantisnow.